Novel membrane-targeted antibiotics against drug-resistant Gram-positive bacterial infections

针对耐药革兰氏阳性细菌感染的新型膜靶向抗生素

• 批准号: nhmrc : 1113719
• 负责人: Dr Mark Blaskovich
• 金额: $ 92.77万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-membrane-targeted-bacterial-infections/663276
• 关键词: Novel; membrane; targeted; antibiotics; against

This project aims to develop a best in class antibiotic, Vancapticin, with superior efficacy, broader spectra of action and improved therapeutic index than existing therapies for Gram-positive (G+ve) bacterial infections. The research team has identified lead candidates that offer equivalent &/or superior potency, efficacy & pharmacokinetic profiles compared to several clinical comparators. NHMRC Development funding is required to select a candidate for an Investigative New Drug application.

该项目旨在开发一种最好的抗生素，Vancapticin，与革兰氏阳性（G+ve）细菌感染的现有疗法相比，具有上级疗效，更广泛的作用谱和改善的治疗指数。研究小组已经确定了与几种临床对照药物相比，提供等同和/或上级效力、疗效和药代动力学特征的主要候选药物。NHMRC开发资金需要选择研究性新药申请的候选人。